Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension of Fesoterodine in Overactive Bladder
NCT00220402Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2004
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fesoterodine in overactive bladder syndrome (OAB), sponsored by Pfizer. Started Jul 2004; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT00220402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220402.